Sanjivani Paranteral Ltd. (BSE: 531569) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹212 Cr, it ranks #2,607 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹171.20 (as of 16 Nov 2026), the share price is 29.8% below its 52-week high of ₹244.00 and 35.9% above its 52-week low of ₹126.00. The share price is down 18.0% over one year and down 10.6% over three months.
| Current Price | ₹171.20 |
|---|---|
| Market Cap | ₹212 Cr |
| BSE Code | 531569 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 31.1 |
| Return on Equity | 14.76% |
| Return on Assets | 6.73% |
| 52-Week Range | ₹126.00 – ₹244.00 |
| 1-Year Price Change | -18.0% |
| 3-Month Price Change | -10.6% |
| Beta (1Y) | 0.94 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanjivani.co.in |
| Revenue | ₹19 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 11.8% |
| EPS (Basic) | ₹1.87 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanjivani Paranteral Ltd. reported revenue of ₹19 Cr in Q1 FY27, up 8.8% from ₹18 Cr in Q1 FY26 and up 85.2% from ₹11 Cr in Q4 FY26. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹2 Cr in Q1 FY26 (up 32.9%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹11 Cr (Q4 FY26) to ₹21 Cr (Q3 FY26). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹19 Cr | ₹2 Cr | 11.8% |
| Q4 FY26 | ₹11 Cr | ₹1 Cr | 8.9% |
| Q3 FY26 | ₹21 Cr | ₹3 Cr | 12.6% |
| Q2 FY26 | ₹16 Cr | ₹2 Cr | 10.6% |
| Q1 FY26 | ₹18 Cr | ₹2 Cr | 9.7% |
| Q4 FY25 | ₹18 Cr | ₹2 Cr | 12.0% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 69.6% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as multivitamins; topicals comprising corticosteroids, antiseptics, NSAIDs, and anti-bacterial; nasal sprays; liquid and dry powder injections covering antibiotics, anti-emetic, NSAID and analgesic, antimalarial, and proton pump inhibitor and H2 receptor antagonist; capsules and tablets, including antibiotic, antifungal, anticonvulsant, multivitamins, and NSAID and analgesic; dry syrups; and ear/eye drops. In addition, the company exports its products. Sanjivani Paranteral Limited was incorporated in 1994 and is headquartered in Mumbai, India.
1. Manufacturing Pharmaceutical Products-This segment offers oral solids, parenterals, and sterile powder formulations. It also provides contract research and manufacturing services.
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Sanjivani Paranteral Ltd. | ₹212 Cr | 31.1 | 14.76% | ₹19 Cr | -18.0% |
Listed by market capitalisation. Ratios are shown for context only.
Sanjivani Paranteral Ltd. is trading at ₹171.20, with a market capitalisation of ₹212 Cr.
Sanjivani Paranteral Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Sanjivani Paranteral Ltd. has a P/E of 31.1 and a return on equity of 14.76%.
Sanjivani Paranteral Ltd. is listed on the BSE under the scrip code 531569.
Sanjivani Paranteral Ltd.'s share price is down 18.0% over one year and down 10.6% over three months. Its 52-week range is ₹126.00 to ₹244.00.
In Q1 FY27, Sanjivani Paranteral Ltd. reported revenue of ₹19 Cr and net profit of ₹2 Cr, with basic EPS of ₹1.87 (standalone, parsed from the company's exchange filing).
Sanjivani Paranteral Ltd. reported revenue of ₹19 Cr in Q1 FY27, up 8.8% from ₹18 Cr in Q1 FY26 and up 85.2% from ₹11 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.